Neurocrine Biosciences Change To Liabilities Over Time
| NBIX Stock | USD 138.64 1.95 1.43% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Neurocrine Biosciences Performance and Neurocrine Biosciences Correlation. Neurocrine |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.512 | Earnings Share 3.75 | Revenue Per Share 22.422 | Quarterly Revenue Growth 0.247 | Return On Assets 0.118 |
The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Change To Liabilities Analysis
Compare Neurocrine Biosciences and related stocks such as Amphastar P, Collegium Pharmaceutical, and Ironwood Pharmaceuticals Change To Liabilities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMPH | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 6.1 M | (3.2 M) | (823 K) | 6.7 M | 29.2 M | (11.7 M) | 20.6 M | 3 M | (736 K) | (846.4 K) | (804.1 K) |
| COLL | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.3 M | 10.5 M | (8.4 M) | 26.1 M | (523 K) | (4.1 M) | (1.1 M) | (11.8 M) | (10.7 M) | (10.1 M) |
| IRWD | 6.2 M | (41.1 M) | (12.1 M) | (18.9 M) | 1.7 M | (8.1 M) | 13.4 M | (6.5 M) | 9 M | (33.2 M) | (7.6 M) | 10.1 M | (7.9 M) | (7.1 M) | (7.5 M) |
| ANIP | 134.1 K | 134.1 K | (4.4 M) | (540 K) | 6.1 M | (5.2 M) | 11.8 M | (3.3 M) | 5.9 M | (1.1 M) | 2.7 M | 2.6 M | 4.9 M | 5.6 M | 5.9 M |
| ALKS | 1.4 M | 17.8 M | 19.4 M | 16.1 M | 59.5 M | 78.8 M | 49.8 M | 77.3 M | 55.7 M | 34.9 M | 60 M | 25.5 M | 28.3 M | 32.5 M | 31.6 M |
| AVDL | 1.2 M | 2.5 M | 2.5 M | 2.5 M | 827 K | (269 K) | 5.2 M | 12.8 M | (13 M) | 5 M | (16 M) | 5.1 M | (3.1 M) | (2.8 M) | (2.7 M) |
| ITCI | 1.3 M | 1.3 M | 4.5 M | 4.5 M | 3.7 M | (4.3 M) | 4.3 M | 3.6 M | 22.2 M | (3.2 M) | (1.7 M) | 3.2 M | 12.4 M | 14.2 M | 15 M |
| PCRX | 4.8 M | 3.6 M | (16.6 M) | 10.4 M | 22.3 M | 14 M | (629 K) | 5.8 M | 5.5 M | 11.7 M | (11.8 M) | (10.1 M) | 6.3 M | 5.6 M | 5.9 M |
| PBH | 5.7 M | 9.7 M | 31.7 M | (16.7 M) | (6 M) | (332 K) | 581 K | (41.5 M) | (259 K) | 18.3 M | (32.3 M) | 18.8 M | 18 M | 16.2 M | 17 M |
| EVO | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | 72.4 M | (16.7 M) | (12.5 M) | 94.4 M | 0.0 | 0.0 | 0.0 |
| SUPN | (869 K) | (869 K) | (869 K) | 9.7 M | 10 M | 3.2 M | 10.8 M | 24.4 M | 4.1 M | (11.9 M) | 8.3 M | 18.2 M | (19.2 M) | (17.2 M) | (16.4 M) |
Neurocrine Biosciences and related stocks such as Amphastar P, Collegium Pharmaceutical, and Ironwood Pharmaceuticals Change To Liabilities description
My Equities
My Current Equities and Potential Positions
| Neurocrine Biosciences | NBIX |
| Classification | Obamacare Repeal |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 138.64
Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.